Skip to content

Summit Therapeutics

US · SMMT #1207 by market cap Listed 2015
9.95 -0.62 -5.87%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $43
    Market Newswire · 2026/10/26
  • Rating change
    Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $37
    Market Newswire · 2026/11/5
  • Rating change
    Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $43
    Market Newswire · 2026/11/6
  • Rating change
    A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $43
    Market Newswire · 2026/9/30
  • Rating change
    Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $20
    Market Newswire · 2026/11/4
  • Leerink Partners Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Announces Target Price $11
    Market Newswire · 2026/11/19
  • A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $16 to $42
    Market Newswire · 2026/11/17
  • Rating change
    Jefferies Upgrades Summit Therapeutics(SMMT.US) to Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/9/9
  • Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Cuts Target Price to $8.3
    Market Newswire · 2026/11/18
  • Rating change
    Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/9/14
  • Rating change
    Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/11/11
  • Rating change
    Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $43
    Market Newswire · 2026/11/5
  • Rating change
    Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20
    Market Newswire · 2026/10/1
  • Rating change
    UBS Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $33
    Market Newswire · 2026/10/26
  • Rating change
    A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $18 to $42
    Market Newswire · 2026/11/16
  • H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Hold Rating
    Market Newswire · 2026/11/18
  • Leerink Partners Upgrades Summit Therapeutics(SMMT.US) to Hold Rating
    Market Newswire · 2026/11/19
  • Rating change
    Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/11/6
  • Rating change
    Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18
    Market Newswire · 2026/9/21
  • Rating change
    Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41
    Market Newswire · 2026/9/14
  • H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Hold Rating
    Market Newswire · 2026/11/5
  • Rating change
    Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/8/27
  • Rating change
    Wolfe Research Initiates Summit Therapeutics(SMMT.US) With Hold Rating
    Market Newswire · 2026/8/17
  • Rating change
    Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $38
    Market Newswire · 2026/7/29
  • Rating change
    Clear Street Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $31
    Market Newswire · 2026/9/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.

Summit Therapeutics discussion 0 comments

Add a comment